Docsun Biomed Report On Actions Taken by FDA On the Use of a Booster Dose for COVID-19 Vaccines

JHUBEI CITY, Taiwan - Nov. 17, 2021 - PRLog -- Docsun Computation Medlab Ltd is on the front line to build an AI-powered Health Monitoring System in a non-invasive and non-contact way. The U.S. Food and Drug Administration took action to expand the use of a booster dose for COVID-19 vaccines in eligible populations. The agency is amending the emergency use authorizations (EUA) for COVID-19 vaccines to allow for the use of a single booster dose as follows:

• The use of a single booster dose of the Moderna COVID-19 Vaccine that may be administered at least 6 months after completion of the primary series to individuals:

Ø 65 years of age and older

Ø 18 through 64 years of age at high risk of severe COVID-19

Ø 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2

• The use of a single booster dose of the Janssen (Johnson and Johnson) COVID-19 Vaccine may be administered at least 2 months after completion of the single-dose primary regimen to individuals 18 years of age and older.
• The use of a single booster dose of the Janssen (Johnson and Johnson) COVID-19 Vaccine may be administered at least 2 months after completion of the single-dose primary regimen to individuals 18 years of age and older.
• The use of a single booster dose of the Janssen (Johnson and Johnson) COVID-19 Vaccine may be administered at least 2 months after completion of the single-dose primary regimen to individuals 18 years of age and older.

DOCSUN on Authorization of "Mix and Match" Booster Dose

Today, the FDA is also authorizing the use of heterologous (or "mix and match") booster dose for currently available (i.e., FDA-authorized or approved) COVID-19 vaccines. Following a presentation of clinical trial data from the National Institute of Allergy and Infectious Diseases, the Vaccines and Related Biological Products Advisory Committee's discussion of information submitted for consideration, along with the agency's evaluation of the available data, the FDA has determined that the known and potential benefits of the use of a single heterologous booster dose outweigh the known and potential risks of their use in eligible populations.

The agency recognizes that health care providers and COVID-19 vaccine recipients will have questions about booster doses. The individual fact sheets for each available vaccine provide relevant information for health care providers and the vaccine recipients.

DocSun∙Computation∙MedLab∙Ltd (https://docsun.health/)∙mission∙is∙using∙technology∙to∙create∙life-long∙ Solutions∙ ∙∙∙The ∙article∙reference∙data∙from∙the∙CDC∙and∙WHO∙

Original links to the article:- https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-takes-additional-actions-use-booster-dose-covid-19-vaccines